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Epstein-Barr virus (EBV) causes infectious mononu­
cleosis as a primary disease. The virus infects more than 
90% of the average population and persists lifelong in 
peripheral B-Iymphocytes. The virus is produced in the 
parotid gland and spread via the oral route. Serology 
suggests that the Epstein-Barr virus might be involved 
in the causation of two neoplastic diseases of humans: 
African Burkitt's lymphoma and nasopharyngeal car­
cinoma. Whereas the development of the lymphoma has 
an even better linkage with chromosomal rearrange­
ments, nasopharyngeal carcinoma shows a unique asso­
ciation with Epstein-Barr virus. Environmental factors, 
including traditional Chinese medicine, may be respon­
sible for the enhanced risk of nasopharyngeal carcinoma 
in certain, predominantly Chinese, populations of south­
ern Asia. Possible mechanisms leading to the establish­
ment of the neoplastic manifestations will be discussed. 
Epstein-Barr virus (EBV), papilloma virus, and hepatitis B 
virus have a few remarkable properties in common. Their 
mobile nucleic acid is DNA that is circular or integrated during 
latency, they persist lifelong in carriers, and they resisted all 
attempts to grow them in vitro in a simple and fully lytic 
system. They are, however, efficiently transmitted in nature, 
where they may cause a more or less severe primary infection 
followed by a lifelong carrier status, indicating the delicate 
interaction of these viruses with their hosts. EBV* was first 
isolated and characterized as a herpes group virus from lym­
phoblastoid cell lines of the B lineage established from African 
Burkitt's lymphomas (BL). Viral particles or structural anti­
gens have never been detected in fresh biopsies. The possibility 
to grow these cell lines from the neoplastic tissue was not only 
technically very helpful, because these cells could be used as an 
antigen source for serologic studies, but it was also supposed to 
be a significant observation as far as the mechanisms of onco­
genicity are concerned. The role of EBV in this process was 
stressed by the fact that B cells of normal umbilical cord blood 
are efficiently immortalized by preparations of EBV. When 
some years after these initial findings marmosets died of lym­
phoproliferative disease after inoculation with EBV, it ap­
peared as if the Henle-Koch postulates for the causation of a 
neoplastic disease of humans by a virus had been fulfilled for 
the first time. 
However, if one looks to the Henle-Koch postulates in their 
original version with all their limitations, especially for assess­
ing secondary or chronic disease, one can see that the situation 
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Abbreviations: 
BL: Burkitt's lymphoma 
EA: early antigens 
EBNA: Epstein�Barr nuclear antigen 
EBV: Epstein-Barr virus 
NPC: nasopharyngeal carcinoma 
PBL: peripheral blood lymphocyte 
TC: Tonsillar carcinoma 
VeA: Viral capsid antigens 
* Most of the data presented in the first part of this paper are 
extensively referenced in available review literature [1-3]. 
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should not be seen as simplistic. The Henle-Koch postulates 
(in a translation of Rivers [4]) are as follows: 
1. The parasite occurs in every case of the disease in question 
and under circumstances that can account for the patho� 
logic changes and clinical course of the disease. 
2. It occurs in no other disease as a fortuitous and nonpath� 
ogenic parasite. 
3. After being fully isolated from the body and repeatedly 
grown in pure culture, it can induce the disease anew. 
For African BL, the first postulate is not fulfilled in only 3% 
of cases. However, clinically very similar lymphomas outside 
Africa-where they are much rarer-can be associated with 
EBV in only 25% of cases. This will be commented on later. 
The second postulate is not exactly fulfilled because EBV is 
regularly associated with infectious mononucleosis, clinically 
inapparent seroconversion and nasopharyngeal carcinoma. The 
third postulate is also not fulfilled in its strict sense because 
the experimentally infected marmosets present with a poly� 
clonal, although fatal, lymphoproliferative disease. This obser­
vation will also be commented on later. 
SEROLOGY OF EBV-RELATED DISEASES 
The B-cell lines that can be established from BL or, as was 
shown later, from anybody's peripheral blood leukocytes aner 
primary EBV infection vary in their ability to produce virus, 
although every single cell contains EBV genomes and expresses 
a nuclear antigen, EBNA. Some cell lines, e.g., one named Raji, 
can be treated with a variety of chemicals, such as IUDR, 
butyric acid, phorbol esters, or cycloleucine. All these com­
pounds are inhibitors of DNA-methylation and induce synthe­
sis of additional virus-related antigens that have been named 
early antigens (EA). Only few cell lines stably produce virus 
and viral capsid antigens (VCA) by spontaneous activation of 
the latent genome in a characteristic fraction of the cells. The 
various cell lines proved of tremendous value for molecular 
biology and seroepidemiology. Using these antigens, the Henles 
and a number of other investigators found that BL patients 
had invariably high antibody levels to EBV -related antigens. 
The seroconversion to EBV positivity of one laboratory tech� 
nician following severe mononucleosis was the initiator of a 
study with college students at Yale that clearly showed that 
EBV is the cause of infectious mononucleosis and that this 
frequent disease of higher socioeconomic groups is the primary 
disease caused by EBV. 
Sera from nasopharyngeal carcinoma revealed similar EBV� 
specific antibody patterns to those observed for BL. Sera from 
a variety of other diseases (Hodgkin's disease, chronic lym� 
phatic leukemia, chronic myel on leukemia, and sarcoidosis, just 
to name some) also showed significantly elevated antibody 
titers. However, in all these cases, a significant fraction of sera 
was negative and antibody levels to other latent viruses (vari­
cella virus, cytomegalovirus) were also elevated. 
INFECTIOUS MONONUCLEOSIS AS THE PRIMARY 
DISEASE CAUSED BY EBV 
Infectious mononucleosis seems to be unknown in such areas 
as the Philippines [5] or Malaysia [6], where infection by EBV 
occurs very early in life and almost everybody has antibodies 
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by the age of 10 years. Clinical symptoms seem to be a conse­
quence of juvenile or adult infection, and one might speculate 
whether a vaccine-primed organism will be infected without 
severe clinical symptoms. 
The clinical diagnosis of infectious mononucleosis is usually 
derived from a combination of four signs: 
1. High leukocyte count ranging from 10,000 to 20,000 and 
reaching up to 50,000 
2. 10% atypical cells 
3. Lymphadenitis 
4. Fever 
The most frequent symptoms are listed in Table 1. 
TABLE 1. Clinical symptoms of infectious mononucleosis 
Symptom 
Enlarged lymph nodes 
Fever 
Pharyngitis 
Tonsillitis 
Splenomegaly 
Hepatomegaly 
Periorbital edema 
Enanthema 
Exanthema 
Jaundice 
Source: Modified from [7]. 
Incidence 
80-100% 
85-98% 
80-95% 
90-98% 
40-90% 
30-40% 
10-30% 
30-50% 
3-15% 
5-10% 
TABLE II. Complications of EBV infection 
1. Hematologic: Agranulocytosis, granulocytopenia, autoimmunohe­
molytic anemia, thrombocytopenia, panmyelopathy 
2. Hepatic: Hepatitis , massive necroses 
3. Neurologic: Cerebellitis, encephalitis, Guillain-Barre syndrome, 
meningoencephalitis, transverse myelitis, SSPE 
4. Renal: Glomerulonephritis, nephrotic syndrome 
5. Cardiovascular: Myocarditis, pericarditis 
6. Respiratory: Acute laryngitis, interstitial pneumonia, bronchopneu­
monia 
7. Others: Arthritis, dermatitis, splenic rupture, immunodeficiency, 
myoglobinuria, subacute thyroiditis, transitory anergia 
8. Neoplastic: Conversion of polyclonal B-cell proliferation to mono­
clonal B-lymphoblast malignancy 
FIG 1. In situ EBV DNA hybridization 
of cryosections of normal parotid gland 
(a, b), normal tonsil (e), and nonkeratin­
izing tonsillar carc inoma (d). Cloned 
EHV DNA that was labeled in vitro with 
["H]thymidine triphosphate by nick 
translation was used as a probe. Note 
that the producing cells (arrow) in the 
parotid glands surround or are present 
in the ducts (a, b), that the normal tonsil 
is EBV-genome-free (c), and that tbe 
tonsillar carcinoma contains EBV -car­
rying cells (arrow) (d). (From Wolf et al 
[29]) 
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Several authors described a much higher prevalence of rash. 
This is, however, in most cases due to a typical concomitant 
hypersensitivity to ampicillin. About 1 percent of the infectious 
mononucleosis cases show one or more of the complications 
listed in Table II, either already at the onset of the disease or 
as a late consequence. Most complications are due to autoim­
mune mechanisms and are in some cases indiscernible from 
graft versus host disease, a mechanism by which the body could 
clear itself from the excess of EBV -converted proliferating B 
cells. 
Under rare circumstances, the T-cell response might be in­
sufficient because of temporary influences such as treatment 
with high doses of cyclosporin A in combination with cortico­
steroids or because of AIDS or a certain genetic predisposition 
as described by Purtilo et al (Duncan's syndrome, XLP, X­
chromosome-linked lymphoproliferative disease) [9). In these 
cases, occasional B cells have a chance to escape host control 
and grow without limitation, as they do when they are kept in 
vitro. The consequences have been described as BL-like disease 
in 3 AIDS patients [10] or as polyclonal lymphoproliferative 
disease for XLP patients [9] or kidney transplant recipients 
[11]. 
The first standard test for the diagnosis of infectious mon­
onucleosis is still the test for heterophile antibodies when 
specific tests are not available. For young children, these tests 
are false negative in up to 30% of cases. EBV -specific antibodies 
TABLE III. Serologic parameter associated with various disease 
conditions 
veA 
Disease EA EB:---IA 
IgG IgM IgA 
Normal adults + + 
Acute adults (early) ++ + + 
Chronic infection + + ± ± 
Reactivation + + + + 
XLP" + + (+) 
NPC ++ + +(D) + 
BL ++ +(R) + 
a XLP as an example of immunologically deprived hosts. 
b Determined by immunoprecipitation of GP 240/200. 
MAb 
+ 
± 
+ 
? 
++ 
+ 
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vary in their value for diagnosing disease. Table III gives the 
appearance and persistence of the antibodies with their respec­
t ive reactivities. 
There is no cure for infectious mononucleosis other than 
time, although the clinical symptoms and the antibody titers 
reportedlv reach normal values much faster, especially in severe 
cases, when the tonsils are removed [12J. The tonsils may be 
the primary site of immunologic defense and the reservoir or 
"recruitment center'· of B-lymphocytes able to proliferate. Fol­
lowing convalescence. about OJ)] "i, of R cells supposedly con­
t ain EBV genomes or EBNA and are able to grow in vitro. The 
chances of growing EBV -immortalized B cells are higher if 
leukocyte preparations are infected with certain strains of EBV 
(e.g., from the B-95-8 marmoset cell line). When this in vitro 
immortalization is done with leukocyte preparations from 
EBV -immune individuals, the T cells have to be removed. At 
least 60<;;, of patients with infectious mononucleosis shed EBV 
in their saliva. Virus shedding does not require special preven­
tion against spreading the disease because epidemics are rare 
and infection of persons in close contact (roommates) is scarce 
[l:\]. Virus shedding does not stop with recovery from disease, 
and at least 30-40% of the adult population sheds EBV. 
NASOPHARYNGEAL CARCINOMA AS A POSSIBLE 
"SECONDARY DISEASE" RELATED TO EBV 
The other disease in which EBV so far shows a 100 percent 
association is nasopharyngeal carcinoma (NPC) [:)1. NPC most 
frequent ly starts at the fossa rosen muelleri at the postnasal 
space, although patients frequently report only after the first 
typical metastases in the cervical lymph nodes have developed. 
The disease has an incidence of up to 40 per 100,000 per year, 
the most frequent neoplasia of humans occurring in some areas 
of southern China and among Chinese in Singapore and Ma­
laysia. The incidence is also elevated in other parts of the 
world, such as Borneo or Tunisia. In most other areas, the 
incidence is around 0.2 per 100,000 per year. The age distribu­
tion shows a clear single peak around the ages of 40 to 50 in 
almost all high-risk areas. There is, however, a second peak at 
an early age, ranging from 5 to 15 years in Borneo and to some 
extent in Tunisia [:lJ. Possible exogenous risk factors will be 
discussed later. A genetic disposition for the disease is difficult 
to test, although the decline of tumor incidence in second­
generation Chinese emigrants to the United States, expecially 
if they live in rural areas, does not support a genetic involve­
ment [1 <l J. The relatively simple HLA patterns of the Chinese 
allowed, however, a significant association of relative risk with 
certain HLA types. A2 and BW46 have elevated relative risks 
of l.5 and l.9, respectively, and of 2.5 if expressed in combi­
nation, and B17 /BW58 is associated with a relative risk of 2.2. 
All, however, is associated with a relative risk of 0.5. Thus a 
relative risk factor of 5.0 exists between the best and the worst 
constellation of HLA types [14J. The neoplasia leads invariably 
to death of the patient, frequently with extensive cranial inva­
sion unless the tumor is recognized early and treated. The most 
successful therapeutic approach is early detection combined 
wit h careful radiation [15], and survival rates exceeding 90% 
have heen reported (Yi Zeng, personal co mmunication ). The 
lise of inexpensive screening methods becomes evident in face 
of the correlation between a rapid decline in survival rates and 
t he elapsed time between the putative earliest detection with 
careful screening and the actual detection of disease and first 
intervention. The determination of IgA anti-VCA antibodies 
has been used with good success to define a group at high risk, 
since :l';, of persons positive in this test had NPC upon clinical 
examinat ion. Bet ween :l.o, and ,0';;; of tumor bearers have IgA 
antibodies to EA; therefore, this test can be used with good 
success as a second screening step. About :10 percent of patients 
positive in the JgA anti-EA test have detectab le NPC [4:3 ] . New 
and improved methods for the detection of viral nucleic acid 
and the development of sampling devices that aspirate cells 
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wit hout taking biopsy [IGJ may further improve the diagnostic 
possibilities. The introduction of single-stranded hybridization 
probes and the availability of label othe r than '"P with its 
inhibitory short half-life have helped to bring nucleic acid 
hybridization over the threshold of a routinely usable method. 
Considering cost-effectiveness, necessary equipment, and sen­
sitivity, we have found that chemical iodination of a collection 
of viral fragments cloned in the single-stranded DNA phage 
m13 gives excellent hybridization probes usable for in situ 
hybridization and bybridization on Southern blots of DNA Of 
spotted DNA or celilysates [44J. 
BURKITT'S LYMPHOMA AND ITS ASSOCIATION 
WITH EBV 
Burkitt's lymphoma has been discussed earlier, and addi· 
tional remarks will be found in the Discllssion section. 
SERUM NO 8588 7070 8483 
-
flNA - 18 32 32 
fA - - 4096 -
VCA - 2042 18384 1024 
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FIG 2. An analysis of EBV-specified polypeptides by immunopre· 
cipitation using sera with different reactivities to EBV -specified anti· 
gens. ND is a serum free of EBV antibodies: 6966 and 846:3 have high 
titers against VCA but not EA; serum 7070 has high titers against both 
VCA and EA. Proteins 138, 88, 45, 40, 38, and :n are only precipitated 
by the EA-positive sera . These results are representative for a much 
larger panel of sera which we have tested. (From Bayliss and Wolj 
{;jli/) 
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FIG :3. a, RNA from induced P:3HRI was hybridized to the cloned EBV Bam fragments and two clones (M ;3-1-1 and M 3-5-6) that subdivide 
the BamA fragment (see map). The bound mRNA was eluted and translated in vitro using the rabbit reticulocyte system. The translation 
products were immunoprecipitated and analyzed on SDS-polyacrylamide gels. 
SOME OPEN PROBLEMS AND APPROACHES TO 
SOLVING THEM 
The presented observations on the involvement of EBV with 
neoplastic and nonneoplastic disease raised a number of ques­
tions that will be discussed in this section: 
1. What is the source of virus in the throat washings of 
apparently healthy persons, and why do apparently nor­
mal individuals who shed virus have antibodies only to 
VCA and EBNA and not to EA, which are produced in 
large amounts during viral replication? 
2. How does the virus infect epithelial cells that apparently 
lack receptors for the virus? 
3. How does the virus persist in cells lifelong, and what are 
the molecular mechanisms underlying the regulated 
expression of EBV? 
1. One might postulate that EBV -carrying lymphocytes in 
the oropharynx that may have escaped host control mecha­
nisms could be the source of the virus that can be obtained 
from healthy individuals. Other studies [17] indicated that EBV 
could be isolated in relatively high titers from saliva collected 
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FIG 3. b, Map of the in vitro translated proteins with hybrid·selected RNA from induced P;3HR1 cells and induced Raj i cells. The Bam 
frag-ments were cloned from H 95-8 derived EBV DNA. By hybridizing to sheared fragments of EBV DNA cloned in Charon 4A, a finer map of 
the coding- reg-ions of some proteins could be achieved. The narrow coding reg-ions for proteins 18,90,47, 73, and 69 in the induced Raj i cells are 
based on t be assumption that these proteins correspond to proteins with the same molecular weights in P3HR1 cells. 
from Stenson's duct. Studies on parotid salivary gland tissue 
[18,19] have suggested that the cells which surround or fill the 
lumen of the ducts of this gland are capable of supporting a 
productive cycle of EB V replication (Fig 1, a, b). Production of 
EBV in salivary duct cells could also explain the absence of 
certain EBV -specific serum antibodies in normal adults (see 
also Discussion). Searches with other tissues of the oropharynx 
(e.g., tonsils from healthy individuals; Fig 1, c) proved negative, 
since no productively infected cell could be found using in situ 
hybridization techniques. This situation resembles somewhat 
that seen with Marek's disease virus, where the transformed 
cells are T cells, but the lytic expression of the virus occurs in 
the germinative epithelium of the feather follicles [20]. In situ 
hybridization studies using tonsillar carcinoma (Te) tissue, 
however, showed that 25% of the specimens tested so far carried 
EBV DNA in the epithelial cells (Fig 1, d). 
2. To date, receptors for EBV have been demonstrated only 
on B-lymphocytes [21] and no other normal nonmalignant cell 
type [3]. How then does the virus enter such cells and persist 
within them? Initially, microinjection of EBV DNA into a wide 
variety of receptor-negative cells [22] and, later, transfection 
with EBV DNA using the calcium phosphate coprecipitation 
technique [23,24] and the implantation of receptors into the 
membranes of receptor-negative cells [25] have been used to 
demonstrate that once EBV overcomes the barrier of penetra­
tion, normal expression of the virus can occur, although syn­
thesis of EBNA was not observed when only lytic expression 
was induced . It was proposed some time ago that syncitium­
inducing viruses, such as paramyxovirus, might induce fusion 
between lymphocytes and epithelial cells, thus allowing the 
virus to gain access to such cells. Since then, we have demon­
strated that EBV itself can induce fusion. When densely packed 
monolayers of lymphoblastoid cells [26] were infected with 
EBV derived from the EBV -producing cell line P3HR1, the 
formation of polykaryocytes could be observed. Further studies 
with mixed monolayers containing both receptor-positive (Raji) 
cells and receptor-negative cells (human fibroblasts, epithelial 
cells, or T -lymphoblastoid cells) showed that an infected EBV· 
antigen-expressing B-lymphoblastoid cell was capable of fusing 
with a noninfected receptor-negative cell [27]. A close cell-to­
cell contact, such as occurs in monolayers, is necessary for the 
development of polykaryocytes. The viral nature of the fusion 
event and the mechanisms involved have been studied in detail 
using chemical activation of latent genomes and various met­
abolic inhibitors. It was shown that an early viral protein was 
responsible for the fusion event [28]. More recent experiments 
[29] have further substantiated the viral origin of the fusion­
inducing protein(s). Purified EBV DNA was transfected into 
unrelated cells (NIH 3T3 cells). In addition to the synthesis of 
EBV EA, fusion of the transfected cells was also observed. 
Further studies with this technique using cloned fragments of 
the EBV genome should permit the mapping of gene(s) encod­
ing the fusion on the EBV genome [29]. 
3. Very little is known at the molecular level of the mecha­
nisms that regulate the response of the cell to infection with 
EBV. As far as we know, all EBV-carrying cell lines express a 
single viral antigen-EBNA. This protein could be the repres­
sor protein that prevents lytic expression. If EBV -carrying cell 
lines are infected with a sufficiently high multiplicity, a lytic 
cycle will occur [30], during which at least 30 virus-induced or 
specific proteins will be synthesized. These proteins can be 
divided into three groups according to their kinetics of synthe­
sis, response to inhibition of DNA synthesis, and requirement 
for virus-specified factors. 
Do these observations have any relevance to regulated 
expression of EBV during the stepwise induction of a lytic cycle 
by the virus in the absence of inhibitors? If Raji cells are 
infected with decreasing amounts of virus, then the interme­
diate and late proteins are no longer synthesized at a certain 
cutoff value [29,31]. 
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However, a certain subset of the EA complex is made, and it 
I' the same subset as that obtained by chemically induced Raji 
cells. Similar observations have been made using an EBV 
�l"lloll1e-negative cell line (B,JA). Immunoprecipitation of EBV 
proteins allows further characterization and a linkage to sero­
logic data. These data (Fig 2) show also that proteins of the 
FA complex are synthesized in considerable amounts during 
the rep lication of EBV; yet normal adults do not have antibod­
ies against these proteins even if they shed virus. 
In an attempt to substantiate further the viral nature of the 
polypeptides and to map the genes on the viral genome, both 
IIf which are essential for detailed studies of the molecular basis 
iorregulation of viral gene expression, we selected mRNA from 
a producer cell line (P:�HR1) by hybridization to cloned EBV 
lJNA fragments. This mRNA was then translated in vitro using 
a rabbit reticulocyte translation system. With this technique 
lI"e were able to identify proteins as EBV -specific and have 
mapped their positions on the EBV genome (Fig 3, a, b) ( Rudolf 
:-Ieibl and Hans Wolf, in preparation) . 
One interesting observation that awaits explanation is that 
if mRNA from EBV-negative cells (B,lA-B) is selected using 
EBV DNA, an mRNA is obtained that hybridizes to the BamHI 
K fragment of the EBV genome. This RNA can be translated 
III vitro to yield polypeptides of 84 kd and 92 kd molecular 
weigbt (Fig 4). This region of the EBV genome is known to 
hybridize to cellular DNA under stringent conditions and may 
Bam R K B 
FI<; 4. R;\lA from HJA-H cells was hybridized to cloned Ram frag­
lllents of ERV as given on top of the gel slots. The hound mHNA was 
eluted and t ran,.;Jated in ,·itm. Translat ion product>; were analyzed on 
SUS-polvHcrvlamide gels. 
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represent cellular sequences that have been incorporated into 
the viral genome during the course of evolution. 
DISCUSSION 
A model has been developed that attempts to include the 
available data and should be useful to predict certain events or 
measurable parameters as well as to design further experiments, 
thus allowing the hypothesis to be further tested (Fig 5). 
1. Normal Situation 
a. Primary infection: Development of antibodies to VCA, EA, 
and EBNA 
As suggested, EBV infects B-Iymphocytes during acute or 
primary infection, and because of the lack of immune response, 
a number of cells enter into the lytic cycle and produce a full 
set of viral antigens (EA and VCA) that are shed into the 
bloodstream. It seems probable that not all B-Iymphocytes are 
capable of supporting a fully lytic infection because of a cellular 
factor that prevents expression of EBV (Fig 5, block 2). These 
cells will be selected for and grow on to become the cells that 
carry EBV latently for the rest of the host's life. 
Because of the release of all the EBV -specified antigens, 
antibodies will be developed against EA, VCA, and EBNA 
(Table III). 
b. Convalescence : Disappearance of antibodies to EA and 
maintenance of antibodies to VCA and EBNA 
As the immune defense mechanisms of the body remove the 
lytically infected cells from the circulation (Fig 5, block 2), the 
antibody levels will start to fall during the convalescent phase. 
After a certain period, antibodies to the EA disappear. However, 
as mentioned above, EBV is produced in the parotid gland. The 
viral particles and intracellular virus-associated antigens in­
cluding EA will be shed into the saliva and reach the orophar­
ynx. Here the viral particles (but not EA) could bind to the B­
lymphocytes and be presented to the body as antigens, thus 
maintaining the antibody titers to VCA. EA cannot bind to the 
lymphocytes and will be degraded by prot eases and not be 
available to the body as antigens. Circulating lymphocytes that 
carry EBV latently contain EBNA and as far as we know no 
other EBV -specified protein. These lymphocytes will be subject 
to the normal turnover processes, and as they die, they will 
release EBNA into the bloodstream. Therefore, antibodies to 
this antigen will persist. As a consequence, normal convalescent 
sera will have low-level IgG anti-VCA and anti-EBNA antibod­
ies Crable III). 
2. Special Conditions 
a. Nonspecific secondary antibody titer increase to VCA and 
EA 
If immunosuppression occurs , either because of other disease 
(e.g., Hodgkin's disease) or because of immunosuppressive ther­
apy, some of the circulating peripheral blood lymphocytes 
(PBLs) will escape the normally tight control mechanism and 
enter into a cycle of virus replication, causing a secondary 
increase in the titers to EA, VCA, and EBNA. 
h. Development of Burkitt's lymphoma (monoclonal disease) 
Under rare circumstances, a cell clone that differs in its 
antigenic makeup may arise and be selected. This clone may 
then lead to the development of BL. Environmental mutagens 
[:�2] and unspecific "mitogens" (malaria ) [3��] that facilitate 
clonal selection through proliferation may favor this event. 
Specific karotypes in the selected clones may correlate to the 
altered antigenic makeup of these cells. 
Follow ing original observations by Manolova et aJ I :j4], sev­
eral authors have indicat ed that chromosomal rearrangements 
occur in all BL cases independent of their association with 
EBV I :j,'j). The most important step seems to be a translocation 
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FIG  5 .  The scheme summarizes the 
suggested biological effects of EBV de­
scribed in the text. Blocks 1 and 2 inhibit 
the lytic expression of EBV, and block 3 
suppresses the proliferation of EBV gen ­
ome containing lymphoid cells in the 
periphery. Block 1 ,  Block at cellular level 
(endogenous block) .  Evidence: Only a 
certain percentage of cells from cloned 
cell lines produce virus. This block is 
responsible for poor production of virus. 
Block 2, Block from the outside (exoge­
nous block, immunologic control?) .  Evi­
dence: In peripheral blood from patients 
with infectious mononucleosis, in fresh 
BL or NPC biopsies no viral particles 
can be found. After explantation into 
tissue culture, a few cells start to produce 
virus. 0 : EHV, 0: activated EBV genes, 
v :  EBV receptors, - : virus-specific 
changes. ( Prom Wolf et at [29} . )  
I n f e c t I O n  
o f  W a l d ey e r 's r i n g  
O 
+ 
O
_IY. la t e n C Y @- l y . ( m a i n t a i n a n c e  
� E B V  � � ---+ of p o p u l a t i o n )  
E B N A  
I 
- b l ock 3 l c y t ogenet i c  error 
u n spec i f i c  st imu lat ion 
clonal  selec t i o n  
l y m p h o m a  
o f  part of the distal arm o f  chromosome 8 carrying the cellular 
oncogene myc to alternate acceptor chromosomes 2 ,  14, or 22,  
respectively . The oncogene is in all  cases translocated to a 
transcriptionally active site close to immunoglobulin genes. 
Whether the transcription of the myc gene after translocation 
is enhanced and what impact this may have are not clear yet 
[36,3 7 ] .  In any case, the involvement of myc alone cannot 
explain the patterns or mechanisms of appearance of BL. 
It should be noted that all  EBV genomes containing B­
lymphoblastoid cells have unlimited growth potential in vitro 
and after intracerebral injection into nude mice. Only the 
lymphoma-derived cells, however, can grow in the nude mouse 
after subcutaneous application [ 3 ] . This behavior seems rather 
suggestive of a loss of control elements on the surfaces of the 
selected clones. One might speculate that HLA or similar 
determinants are altered or lost during the process of clonal 
selection. 
Transfection experiments have shown that two oncogenes 
frequently may be involved in oncogenesis [38] . Such a model 
could include an EBV gene as a possible member of a comple ­
mentation group of oncogenes and myc as a member of another 
group. Thus EBV might still play a major role in the causation 
of African BL.  
c .  Development of polyclonal proliferative disease 
Specific genetic constellations (XLP) or acquired conditions 
( immunosuppressed transplant recipients, AIDS patients; see 
above) determine a reduced efficiency of block 3 (cellular re­
sponse to proliferating cells ) .  Therefore, the selective pressure 
on peripheral B -Iymphocytes (which already have a potential 
for unlimited growth by virtue of the resident EBV genomes) 
may be weaker. Under less stringent selective pressure, more 
cells may proliferate in vivo and lead to a polyclonal lymphoma 
[9] . Nonspecific growth stimuli such as the graft may favor 
initial proliferation and facilitate the selection of cell clones . A 
specific cytogenetic error [39]  may occur under therapy and 
may induce a change from polyclonality to monoc\onality . 
d. Relation to T -cell leukemia 
As a side effect of primary EBV infection , the initial prolif­
eration of B-Iymphocytes due to the early absence of block 2 
apparently leads to a proliferation of T-lymphocytes [8] . This 
may well be caused by growth factors . This polyclonal activa­
tion of T - lymphocytes may occasionally activate T cells with 
malignant growth potential and lead to a T-cell leukemia 
following infectious mononuc leosis . 
e. Development of nasopharyngeal carcinoma 
On the specific conditions of the site of initiation of lym­
phoepithelial tumors. A close contact between epithelial cells 
and B-lymphocytes that may carry EBV genomes has been 
�escribed for the lymphoepithelial ring of the throat (Waldey­
er's ring) . This unique tissue may provide the necessary con­
ditio�s for EBV -induced fusion between the two cell types, thus 
enablmg the EBV genome to enter the epithelial cells. If this 
hypothesis is true, then EBV should be associated with other 
tumors that arise within this tissue. Evidence for this associa­
tion has been independently derived by our group [ 28] and by 
Brichacek et al [40 ] . The major difference between TC and 
NPC is that only 25% of the limited number of TCs so far 
tested were serologically related to EBV, whereas all NPCs are 
EBV -genome -positive. At the moment, we cannot explain these 
findings . This proposal would be in good agreement with the 
proffered model. 
On the role of environmental factors on the relative risk of 
NPC. It has been observed that certain plant extracts can 
induce latent EBV and somehow increase the risk for NPC 
[41 ] .  Croton oil was one of the first suspected medications. 
However, it is highly irritating and is used only under close 
medical supervision and is therefore unlikely to be an NPC­
related risk factor. More recently, Zeng et al [42] have tested 
over 500 different extracts from 100 plant families and found 
that 20 of them were capable of activating latent EBV. Some 
of the extracts were active as aqueous extracts and thus open 
the possibility that traditional Chinese herbal medicine often 
applied as teas, may contain EBV-inducing principle� . One 
difference in the EBV serology of the populations with low and 
high risk for NPC development is that in high-risk areas the 
level of antibody to EBV antigens remains high throughout life 
when compared with low- risk populations (Yi Zeng and Shu 
Yan Gu, personal communication) .  Thus EBV -activating sub­
stances could continuously stimulate the latently infected B 
cells to enter into a lytic cycle, explaining the differences in 
July 1 984 
antibody titers. If follow-up studies could demonstrate a match 
between the areas with high risk for NPC and the use of the 
discussed plant extracts, a multifactorial causation of NPC 
would be substantiated. 
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